

| Award Principal Investigator | Award Organization Name | Sponsor Name | Award Name | Award Start Date | Award End Date | Funded Amount | Total Award Amount |
|------------------------------|----------------------------------|--|---|------------------|----------------|---------------|--------------------|
| Amberg, David C | 110 Vice President for Research | SUNY Upstate Medical University | SUNY Hill: Urinary arsenic and health (including cardio and neuroendocrine disruption) in Syracuse children | 01-Jan-2020 | 01-Aug-2021 | 2.00 | 2.00 |
| Kotula, Leszek | 110 Surgery - Urology | Health Science Center Foundation at Syracuse | Al Todeschini Pancreatic Cancer Fund | 01-Jan-2020 | 31-Dec-2021 | 5,000.00 | 5,000.00 |
| Fortner, Christopher N | 110 Pediatrics | Vertex Pharmaceuticals Incorporated | A Phase 3, Open-label Study Evaluating the Long term Safety of VX-445 Combination Therapy in Subjects with Cystic Fibrosis | 09-Dec-2019 | 08-Dec-2020 | 129,248.00 | 129,248.00 |
| Endy, Timothy P. | 110 Microbiology | Balance-Multiple Sponsors | Balance Account for Funds from Janssen Account for Ongoing Project with Grenada | 01-Jan-2020 | 31-Dec-2024 | 91,886.27 | 91,886.27 |
| Urao, Norifumi | 110 Pharmacology | University of Illinois at Chicago | Targeting leukocyte traffic in intestinal inflammation | 01-Nov-2019 | 31-Oct-2020 | 10,219.00 | 10,219.00 |
| Weinstock, Dr. Ruth S | 110 Medicine | Insulet Corporation | Evaluating the Safety and Effectiveness of the Omnipod Horizon Automated Glucose Control System in Patients with Type 1 Diabetes | 04-Dec-2019 | 03-Dec-2021 | 395,731.08 | 395,731.08 |
| Martinez-DeLuna, Reyna I | 110 Ophthalmology | Research to Prevent Blindness | RPB Career Development Award - The role of B2- and y3- containing laminins in the development of intrinsically photosensitive ganglion cells | 01-Jan-2020 | 31-Dec-2020 | 75,000.00 | 75,000.00 |
| Ridilla, Jessica L. | 110 Cell & Developmental Biology | Sinsheimer Foundation | Mechanisms of actin and microtubule crosstalk in neurodegenerative disease | 01-Jan-2020 | 31-Dec-2020 | 100,000.00 | 100,000.00 |
| Amberg, David C | 110 Vice President for Research | CenterState Corporation for Economic Opportunity | New York State Innovation Hot Spot and Incubator | 01-Jan-2020 | 31-Dec-2020 | 50,000.00 | 50,000.00 |
| Beach, Dr. Robert L | 110 Neurology | UCB Biopharma SPRL | An Open-Label, Multicenter, Extension Study to Evaluate the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects with Drug-Resistant Epilepsy | 04-Dec-2019 | 03-Dec-2021 | 27,055.00 | 27,055.00 |
| Bogart, Dr. Jeffrey A | 110 Radiology Oncology | Radiation Therapy Oncology Group | A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features RTOG Study 3506 (Pfizer) | 25-Jan-2019 | 06-Jun-2021 | 9,000.00 | 9,000.00 |
| Lavelle, Dr. William F. | 110 Surgery - Orthopedics | Cerapedics Incorporated | An Assessment of P-15L Bone Graft in Transforaminal Lumbar Interbody Fusion with Instrumentation | 13-Jan-2020 | 12-Jan-2021 | 8,500.00 | 8,500.00 |
| Monteleone, Philip | 110 Pediatrics | Children's Hospital of Philadelphia | Per Case Reimbursement: COG NCORP Research Base | 02-Sep-2019 | 31-Jul-2021 | 1.00 | 1.00 |
| Thomas, Stephen J. | 110 Medicine | Adelphi Values Limited | Ecuador Cohort Study - MS7972A Qualitative Interview Study | 09-Sep-2019 | 08-Sep-2021 | 54,293.64 | 54,293.64 |
| Monteleone, Philip | 110 Pediatrics | Children's Hospital of Philadelphia | One Time EOY, Integrated BIQSFP AAML1031 - Echocardiogram Reports and Images | 24-May-2019 | 28-Feb-2021 | 1.00 | 1.00 |
| Young, Eufrosina I. | 110 Neurology | Massachusetts General Hospital | HEALEY ALS Platform Trial related to Amyotrophic Lateral Sclerosis | 06-Dec-2019 | 05-Dec-2021 | 2,500.00 | 2,500.00 |
| Kerr, Dr. William G. | 110 Microbiology | Alterna Therapeutics Incorporated | Novel and potent SHP1 inhibitors for improving hematologic recovery following myelosuppressive therapies | 10-Jun-2019 | 31-May-2021 | 105,994.00 | 105,994.00 |
| Lin, Yingxi | 110 Psychiatry | National Inst of Neurological Disorders & Stroke | Activity dependent transcriptional pathways underlying synaptic mechanisms for memory discrimination & generalization | 01-Mar-2020 | 31-Dec-2020 | 610,894.00 | 2,770,617.00 |
| Kotula, Leszek | 110 Surgery - Urology | Health Science Center Foundation at Syracuse | Leukemia and Related Disorders Research | 01-Feb-2020 | 31-Jan-2022 | 50,000.00 | 50,000.00 |
| Basnet, Alina | 110 Medicine | Janssen Research and Development LLC | A Phase 3 Randomized, Placebo-controlled, Double-blind Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Subjects with Metastatic Prostate Cancer | 17-Dec-2019 | 16-Dec-2021 | 30,516.00 | 30,516.00 |
| Perl, Dr. Andras | 110 Medicine | Pfizer Incorporated | A Phase 2B, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose-Ranging Study to Evaluate the Efficacy and Safety Profile of PF-06700841 in Participants with Active Systemic Lups Erythematosus (SLE) | 12-Feb-2020 | 11-Feb-2021 | 18,750.00 | 18,750.00 |
| Mejico, Dr. Luis | 110 Neurology | Amgen Incorporated | Effect of Erenumab-aoee on Disability and Work Productivity in Employed Subjects With Episodic Migraine Who Have Previously Failed 1 or More Migraine Preventive Treatments | 19-Feb-2020 | 18-Feb-2021 | 13,000.00 | 13,000.00 |
| Weinstock, Dr. Ruth S | 110 Medicine | Jaeb Center for Health Research Incorporated | Glycemic Variability and Fluctuations in Cognitive Status in Adults with Type 1 Diabetes (GluCog) | 13-Jan-2020 | 12-Jan-2021 | 26,427.06 | 26,427.06 |
| Monteleone, Philip | 110 Pediatrics | Children's Hospital of Philadelphia | A Phase III Randomized, Open label, Multi-center Study of the Safety and Efficacy of Apixaban for Thromboembolism Prevention versus No Systemic Anticoagulant Prophylaxis during Induction Chemotherapy in Children w/ lymphoblastic Leukemia | 02-Jul-2019 | 01-Jul-2021 | 9,053.00 | 9,053.00 |

| | | | | | | | |
|----------------------------|--|--|--|-------------|-------------|------------|--------------|
| Suryadevara, Manika D | 110 Pediatrics | Janssen Research and Development LLC | A Phase 2, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Relationships of Different Doses of JNJ-53718678 in Children >=28 days & 3 yr | 02-Jan-2020 | 01-Jan-2021 | 16,905.00 | 16,905.00 |
| Paolino, Mr. Kristopher | 110 Medicine | Sanofi Pasteur Incorporated | Phase I/II, randomized, observer-blind, dose-ranging (4 Log CCID50/dose; 5 Log CCID50/dose, 6 Log CCID50/dose), YF-VAX-controlled, multi-center study in 572 adults in USA | 27-Feb-2020 | 26-Feb-2021 | 62,800.00 | 62,800.00 |
| Albright, Karen C. | 110 Neurology | University of Cincinnati | Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE) | 01-Jul-2019 | 30-Apr-2021 | 1.00 | 1.00 |
| Poiesz, Dr. Bernard J | 110 Medicine | Acerta Pharma | Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination with Rituximab in Subjects with Indolent B-cell Non-Hodgkin Lymphoma | 18-Feb-2020 | 17-Feb-2021 | 14,850.00 | 14,850.00 |
| Lin, Yingxi | 110 Psychiatry | International Human Frontier Science Program Org | HFSP Fellowship for Jian Xue | 01-Mar-2020 | 15-Aug-2020 | 30,682.64 | 30,682.64 |
| Thangamani, Saravanan | 110 Microbiology | Campus SF Accounts Multiple Sponsors | Vector Biology Lab | 01-Mar-2020 | 28-Feb-2021 | 2.00 | 2.00 |
| Thangamani, Saravanan | 110 Microbiology | Multi Funding | Third Party Revenue Award for Vector Biology Lab | 01-Mar-2020 | 28-Feb-2021 | 1.00 | 1.00 |
| Liu, Chunyu | 110 Psychiatry | University of California at Los Angeles | Discovery and validation of neuronal enhancers associated with the development of psychiatric disorders | 01-Oct-2019 | 30-Apr-2021 | 102,600.00 | 102,600.00 |
| Wojtowycz, Martha A | 110 OB/GYN | Onondaga County | Syracuse Healthy Start Grant - Eliminating Disparities in Perinatal Health | 01-Apr-2019 | 31-Mar-2020 | 28,000.00 | 28,000.00 |
| Lavelle, Dr. William F. | 110 Surgery - Orthopedics | Spinal Kinetics Incorporated | M6-C Artificial Cervical Disc IDE Post-Approval Study | 27-Feb-2020 | 26-Feb-2021 | 5,000.00 | 5,000.00 |
| Luo, Juntao | 110 Pharmacology | Empire State Development Corp | NYFIRST Medical School Grant Program | 20-Feb-2020 | 28-Feb-2021 | 222,500.00 | 222,500.00 |
| Paolino, Mr. Kristopher | 110 Microbiology | University of Washington | COVID-19: Post exposure prophylaxis clinical trial | 30-Mar-2020 | 31-Mar-2021 | 694,185.00 | 694,185.00 |
| Weiner, Dr. Leonard B | 110 Pediatrics | ModernaTX | A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus Type 3 (PIV3) Vaccine-Adults & 12-36 mo. | 28-Jan-2020 | 27-Jan-2021 | 11,500.00 | 11,500.00 |
| Manzella, Lorraine L | 110 College of Medicine - Curr | Upstate University Medical Associates at Syracuse Incorporated | COVID-19 Staff Leasing | 01-Apr-2020 | 31-Dec-2021 | 2.00 | 2.00 |
| Holz, George G | 110 Medicine | National Inst of Diabetes Digestive Kidney Disease | Alpha 7 nicotinic acetylcholine receptor regulation of glucagon like peptide 1 incretin hormone action | 01-Feb-2020 | 31-Jan-2021 | 405,001.00 | 1,620,978.00 |
| Thomas, Stephen J. | 110 Medicine | Janssen Global Public Health | Pre-Study Start-Up Clinical Services for Protocol 64281802DNG2001 A Phase 2a . . . Trial to Evaluate the Antiviral Activity . . . of Repeated Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Challenge Model | 14-Apr-2020 | 15-May-2020 | 41,881.48 | 41,881.48 |
| Austin-Ketch, Tammy L | 110 Dean - College of Nursing | Mary Imogene Bassett Hospital | Advanced nurse education-nurse practitioner residency program | 01-Jul-2019 | 01-Oct-2020 | 100,000.00 | 100,000.00 |
| Faraone, Stephen V | 110 Psychiatry | Massachusetts General Hospital | Discoveries in ADHD genomics: help or hype in clinical settings | 01-Aug-2019 | 31-May-2021 | 92,998.00 | 92,998.00 |
| Liu, Chunyu | 110 Psychiatry | National Institute of Mental Health | 1/3 high resolution mapping of cell type specific DNA (hydroxy)methylation in the human brain during postnatal development and in psychiatric disease | 01-May-2020 | 28-Feb-2021 | 161,151.00 | 805,755.00 |
| Sullivan, Ross W | 110 Emergency Medicine | McLean Hospital Corporation | The National Drug Abuse Treatment Clinical Trial Network | 01-Mar-2020 | 31-May-2020 | 135,520.00 | 135,520.00 |
| Beissner, Katherine L. | 110 Dean - College of Health Professions | NYS Department of Health | Medical Scholars Program | 01-Sep-2019 | 31-Aug-2020 | 15,000.00 | 15,000.00 |
| Weinstock, Dr. Ruth S | 110 Medicine | Lilly USA LLC | A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants with Type 1 Diabetes Mellitus Previously Treated with Multiple Daily Injection Therapy | 17-Mar-2020 | 16-Mar-2021 | 8,250.00 | 8,250.00 |
| Bernstein, Audrey M. | 110 Ophthalmology | National Eye Institute | Cellular dysfunction in exfoliation glaucoma | 01-Jun-2020 | 31-May-2021 | 426,768.00 | 1,660,572.00 |
| Gibson-Speicher, Jennifer | 110 Pediatrics | Health Science Center Foundation at Syracuse | Margaret L. Williams Developmental Evaluation Center Fund #48800 | 01-Jan-2020 | 31-Dec-2020 | 12,901.08 | 12,901.08 |
| Paolino, Mr. Kristopher | 110 Microbiology | University of Washington | COVID-19: mild disease therapeutic trial | 15-Apr-2020 | 14-Apr-2021 | 496,217.00 | 496,217.00 |
| Schmidt, Elena | 110 Neurology | University of Cincinnati | StAtins Use in intracerebral hemorrhage patients (SATURN) | 01-Sep-2019 | 31-May-2021 | 4,287.50 | 4,287.50 |
| Paolino, Mr. Kristopher | 110 Medicine | Lilly USA LLC | A Randomized, Double-blind, Placebo-controlled, Clinical Trial of LY3127804 in Patients who are Hospitalized with Pneumonia and Presumed or Confirmed COVID-19 | 01-May-2020 | 30-Apr-2021 | 79,066.00 | 79,066.00 |
| Pellegrino, Joan E | 110 Pediatrics | NYS Department of Health | Genetic Disease Screening Institutional Support | 01-Oct-2019 | 30-Sep-2020 | 36,092.00 | 36,092.00 |
| Stork-Medicis, Christine M | 110 Emergency Medicine | Health Resources and Services Admin | CARES funding for poison centers | 01-Apr-2020 | 31-Mar-2021 | 113,006.00 | 113,006.00 |
| Sexton, James F | 110 Medicine | Cystic Fibrosis Foundation | Award for Physical Therapist | 01-Apr-2020 | 31-Mar-2021 | 32,145.00 | 32,145.00 |

| | | | | | | | |
|-------------------------|----------------------------------|---|--|-------------|-------------|--------------|--------------|
| Bratslavsky, Gennady | 110 Surgery - Urology | Progenics Pharmaceuticals Incorporated | A multicenter, Randomized, controlled phase 2 study: Efficacy and safety of I-131-1095 Radiotherapy in combination with enzalutamide in metastatic castration-resistant prostate cancer (mCRPC) patients Who are F-DCFPyL prostate-specific. . . | 04-May-2020 | 03-May-2021 | 21,250.00 | 21,250.00 |
| Wali, Prateek D | 110 Pediatrics | Massachusetts General Hospital | Detection of Serum Protein Biomarkers to Predict and Monitor Response to Infliximab Using SOMAscan | 01-Jan-2019 | 31-Dec-2020 | 3,000.00 | 3,000.00 |
| Durdon, Kathi G | 110 Vice President for Research | FuzeHub | Catheter and Insertion Aid Mold Development | 04-May-2020 | 03-May-2021 | 20,000.00 | 20,000.00 |
| Bailey, Dr. R Eugene | 110 Family Medicine | March of Dimes Foundation New York State Chapter | IMPLICIT: implementing interconception care at Upstate Family Medicine Health Centers | 01-Jun-2020 | 31-May-2021 | 50,000.00 | 50,000.00 |
| Sexton, James F | 110 Medicine | Cystic Fibrosis Foundation | Implementation of outpatient clinical pharmacy services: award for pharmacist and/or pharmacy technician | 01-Apr-2020 | 31-Mar-2021 | 29,160.00 | 29,160.00 |
| Graziano, Dr. Stephen L | 110 Medicine | Novartis Pharmaceuticals Corporation | A randomized, open-label, phase II study of canakinumab or pembrolizumab as monotherapy or in combination as neo-adjuvant therapy in subjects with resectable non-small cell lung cancer (CANOPY-N) | 11-May-2020 | 04-Jul-2022 | 18,225.00 | 18,225.00 |
| Mihaila, Dr. Dragos | 110 Neurology | Cerevel Therapeutics | A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson's Disease (TEMPO-2 Trial) | 13-May-2020 | 12-May-2021 | 9,000.00 | 9,000.00 |
| Faraone, Stephen V | 110 Psychiatry | Supernus Pharmaceuticals Incorporated | Research Services Agreement | 18-May-2020 | 17-May-2022 | 64,666.00 | 64,666.00 |
| Izadyar, Shahram | 110 Neurology | Otsuka Pharmaceutical Development and Commercialization Inc | A Phase 1b, Single-blind, Placebo-controlled, Adaptive Design, Outpatient Trial to Assess the Effects of Single Oral Tablet Doses of OPC-214870 on Photic-induced Paroxysmal Electroencephalogram Responses in Subjects Who have Demonstrated... | 01-Oct-2019 | 28-Feb-2021 | 13,000.00 | 13,000.00 |
| Thomas, Stephen J. | 110 Microbiology | University of Maryland Baltimore | Clinical core for collaborative influenza vaccine innovation centers (CIVICs): Design & execution | 16-Sep-2019 | 15-Sep-2020 | 57,435.00 | 57,435.00 |
| Thomas, Stephen J. | 110 Medicine | Pfizer Incorporated | A Phase 1/2, Placebo-Controlled, Randomized, Observer-Blind, Dose-Finding Study to Describe the Safety, Tolerability, Immunogenicity, and Potential Efficacy of SARS-CoV-2 RNA Vaccine Candidates Against COVID-19 in Healthy Adults | 06-May-2020 | 05-May-2021 | 1,293,416.05 | 1,293,416.05 |
| Setter, Mr. Kevin J | 110 Surgery - Orthopedics | Integra Lifesciences Incorporated | A Post-Market, Prospective, Multi-Center, Open-Label, Single Arm Clinical Evaluation of the Integra? Titan? Modular Shoulder System 2.5 for Primary Shoulder Joint Replacement | 24-Jun-2020 | 23-Jun-2021 | 5,000.00 | 5,000.00 |
| Calvert, Dr. Peter D | 110 Ophthalmology | Research to Prevent Blindness | Research to Prevent Blindness Stein Innovation Award | 01-Jul-2020 | 30-Jun-2021 | 150,000.00 | 150,000.00 |
| Ganapathy, Preethi S. | 110 Ophthalmology | Research to Prevent Blindness | RPB Career Development Award | 01-Jul-2020 | 30-Jun-2021 | 75,000.00 | 75,000.00 |
| Bah, Alaji | 110 Biochemistry | National Institute of General Medical Sciences | Role of DNA Methylation in Liquid-liquid Phase Separation-mediated Heterochromatin Formation | 01-Jul-2020 | 30-Jun-2021 | 405,000.00 | 2,025,000.00 |
| Thomas, Stephen J. | 110 Medicine | RMS Allocation Account | IDC Recovery for Global Health | 01-Jul-2020 | 30-Jun-2021 | 15,164.00 | 15,164.00 |
| Perl, Dr. Andras | 110 Medicine | National Inst of Arthritis Musculoskeletal & Skin | SLE Treatment with N-acetylcysteine | 15-Jun-2020 | 31-May-2021 | 1,500,000.00 | 7,269,926.00 |
| Luo, Juntao | 110 Pharmacology | Health Science Center Foundation at Syracuse | A translational study of a novel nanotrap for sepsis treatment using patient blood samples | 01-Jun-2020 | 31-May-2021 | 50,000.00 | 50,000.00 |
| Olson, Dr. Eric C. | 110 Physiology | Health Science Center Foundation at Syracuse | Ethanol induced silencing of kinase signaling during brain development | 01-Jun-2020 | 31-May-2021 | 75,000.00 | 75,000.00 |
| Loh, Dr. Stewart N | 110 Biochemistry | Health Science Center Foundation at Syracuse | Mechanism and detection of LECT2 amyloidosis | 01-Jun-2020 | 31-May-2021 | 50,000.00 | 50,000.00 |
| Krendel, Mira F | 110 Cell & Developmental Biology | Health Science Center Foundation at Syracuse | Assay development for analysis of the motor activity of class I myosins | 01-Jun-2020 | 31-May-2021 | 50,000.00 | 50,000.00 |
| Knutson, Bruce A. | 110 Biochemistry | Health Science Center Foundation at Syracuse | Directed evolution approach to investigate the structure based DNA binding mechanism of RNA polymerase I core factor | 01-Jun-2020 | 31-May-2021 | 50,000.00 | 50,000.00 |
| Wentz, Erin E. | 110 Physical Therapy | Health Science Center Foundation at Syracuse | The SPROUT project: starting pregnancy with robustness for optimal upward trajectories | 01-Jun-2020 | 31-May-2021 | 17,948.00 | 17,948.00 |
| Hu, Huaiyu | 110 Physiology | Health Science Center Foundation at Syracuse | Generation of EYS mutant marmoset embryos | 01-Jun-2020 | 31-May-2021 | 40,000.00 | 40,000.00 |
| Kim, Bokkyu | 110 Physical Therapy | Health Science Center Foundation at Syracuse | Promoting fine hand motor skill learning in chronic survivors using transcranial photobiomodulation | 01-Jun-2020 | 31-May-2021 | 19,983.00 | 19,983.00 |
| Meyer, Jenny A. | 110 Medicine | MediciNova | A Phase 2B/3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, 12 Month Clinical Trial to Evaluate the Efficacy and Safety of MN-166 (Ibudilast) Followed by an Open-Label Extension in Subjects with ALS (COMBAT-ALS) | 11-May-2020 | 10-May-2021 | 11,500.00 | 11,500.00 |
| Nieman, Gary F | 110 Surgery - General | Transonic System Incorporated | Animal Study | 01-Apr-2020 | 31-Mar-2021 | 62,594.00 | 62,594.00 |

| | | | | | | | |
|---------------------------|---|---|--|-------------|-------------|--------------|--------------|
| Moffat, Dr. Jennifer F | 110 Microbiology | XBiotech USA Incorporated | Evaluation of antibodies for effects on VZV infection | 08-Jul-2020 | 31-Dec-2020 | 11,570.00 | 11,570.00 |
| Sullivan, Ross W | 110 Emergency Medicine | Yale University | The National Drug Abuse Clinical Trials Network: New England consortium node CTN-0099 | 01-Jun-2020 | 28-Feb-2021 | 291,553.00 | 291,553.00 |
| Brangman, Dr. Sharon A | 110 Geriatrics | Icahn School of Medicine at Mount Sinai | Recruitment accelerator for diversity in aging research, cognitive loss and dementia (RADAR-CLD) | 15-Feb-2020 | 30-Nov-2020 | 71,155.00 | 71,155.00 |
| Smith, Eric J. | 110 Vice President for Finance & Management | Multiple Sponsors - Nonsponsored | COVID SUNY Testing Kits - Quadrant | 01-Jul-2020 | 30-Jun-2021 | 1,800,835.00 | 1,800,835.00 |
| Monteleone, Philip | 110 Pediatrics | Children's Hospital of Philadelphia | A Phase III Study of 131I Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL) [Study: COG ANBL1531 - Jubilant Draximage Inc] | 17-Jul-2020 | 16-Jul-2021 | 1.00 | 1.00 |
| Schwartz, Dr. Thomas L | 110 Psychiatry | LivaNova USA Incorporated | RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | 25-Jun-2020 | 24-Jun-2021 | 11,500.00 | 11,500.00 |
| Paolino, Mr. Kristopher | 110 Medicine | Regeneron Pharmaceuticals Incorporated | A Master Protocol Assessing the Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Hospitalized Patients with COVID-19 | 18-Jul-2020 | 17-Jul-2021 | 14,490.00 | 14,490.00 |
| Endy, Timothy P. | 110 Microbiology | Advanced Technology International | Dengue Human Infection Model (Clinical Trial Portion) | 20-Sep-2018 | 09-Jul-2021 | 343,639.00 | 343,639.00 |
| Beissner, Katherine L. | 110 Dean - College of Health Professions | Health Science Center Foundation at Syracuse | The Summer Intensive Health Professions Prep | 01-Jul-2020 | 30-Jun-2021 | 6,660.00 | 6,660.00 |
| Beach, Dr. Robert L | 110 Neurology | Cerevel Therapeutics | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER TRIAL OF CVL-865 AS ADJUNCTIVE THERAPY IN ADULTS WITH DRUG-RESISTANT FOCAL ONSET SEIZURES (REALIZE TRIAL) | 13-May-2020 | 12-May-2021 | 12,000.00 | 12,000.00 |
| Paolino, Mr. Kristopher | 110 Medicine | SAB Biotherapeutics | A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of SAB-185 in Healthy Subjects | 17-Jul-2020 | 16-Jul-2021 | 65,838.40 | 65,838.40 |
| Bhargava, Ramya | 110 Medicine | Icahn School of Medicine at Mount Sinai | North East Consortium for Transplant outcomes in APOL1 kidney Recipients (NECTAR) Clinical Center | 22-Aug-2019 | 31-May-2021 | 2,000.00 | 2,000.00 |
| Hansen, David | 110 Pediatrics | Insulet Corporation | Evaluating the Safety and Effectiveness on the Omnipod Horizon Automated Glucose Control System in Children with Type 1 Diabetes Aged 2.0-5.9 Years: Preschool Cohort | 28-Jul-2020 | 27-Jul-2021 | 6,547.00 | 6,547.00 |
| Poiesz, Dr. Bernard J | 110 Medicine | UCB Biopharma SPRL | A Phase 3 Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants with Persistent or Chronic Primary Immune Thrombocytopenia (ITP) | 29-Jul-2020 | 28-Jul-2021 | 16,300.00 | 16,300.00 |
| Weiner, Dr. Leonard B | 110 Pediatrics | Pfizer Incorporated | A Phase 3, Randomized, Double-Blind Trial To Evaluate The Safety And Immunogenicity Of A 20-Valent Pneumococcal Conjugate Vaccine In Healthy Infants | 08-Jul-2020 | 07-Jul-2021 | 31,663.89 | 31,663.89 |
| Mihaila, Dr. Dragos | 110 Neurology | NeuroDerm | A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD . . . | 21-Jul-2020 | 20-Jul-2021 | 13,000.00 | 13,000.00 |
| Meuser-Herr, Nathaniel D. | 110 Pediatrics | Mother Cabrini Health Foundation | Protecting immigrant dairy workers in New York from COVID-19 | 01-Jul-2020 | 31-Dec-2020 | 50,000.00 | 50,000.00 |
| Thomas, Stephen J. | 110 Medicine | Janssen Pharmaceutica NV | A Phase 2a, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Repeated Oral Doses of JNJ-64281802 Against Dengue Serotype 1 Infection in a Dengue Human Infection Model. . . | 13-Jul-2020 | 12-Jul-2021 | 191,946.41 | 191,946.41 |
| Pawar, Snehalata A. | 110 Radiology Oncology | Myelo Therapeutics GmbH | Development of Myelo001 as an orally applied medical countermeasure for the treatment of hematopoietic acute radiation syndrome | 01-Aug-2020 | 30-Apr-2021 | 24,975.00 | 24,975.00 |
| Paolino, Mr. Kristopher | 110 Medicine | Janssen Research and Development LLC | A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical COVID 19 Disease | 10-Aug-2020 | 09-Aug-2021 | 18,750.00 | 18,750.00 |
| Basnet, Alina | 110 Medicine | Janssen Research and Development LLC | Biomarker Study to Determine Frequency of DNA-repair Defects in Men with Metastatic Prostate Cancer | 01-Jul-2020 | 30-Jun-2021 | 10,650.00 | 10,650.00 |
| Hu, Huaiyu | 110 Physiology | National Eye Institute | The roles of EYS in photoreceptor health | 01-Sep-2020 | 30-Jun-2021 | 243,000.00 | 445,500.00 |
| Kong, Yanping | 110 Medicine | Health Science Center Foundation at Syracuse | Turn 4 a Cure | 01-Jul-2020 | 30-Jun-2022 | 12,500.00 | 12,500.00 |
| Fortner, Christopher N | 110 Pediatrics | Cystic Fibrosis Foundation | TDC Principal Investigator Protected Effort (PIPE) | 01-Apr-2020 | 31-Mar-2021 | 27,306.00 | 27,306.00 |
| Kuznetsov, Vladimir | 110 Surgery - Urology | Health Science Center Foundation at Syracuse | Turn 4 a Cure | 01-Jul-2020 | 30-Jun-2022 | 12,500.00 | 12,500.00 |
| Thangamani, Saravanan | 110 Microbiology | University of Texas Medical Branch at Galveston | Safety and immunogenicity of a novel Rift Valley fever candidate vaccine, RVax-1 | 10-Mar-2020 | 28-Feb-2021 | 87,865.00 | 87,865.00 |

| | | | | | | | |
|-------------------------|---------------------------|--|--|-------------|-------------|------------|--------------|
| Mollapour, Mehdi | 110 Surgery - Urology | US Army Medical Research Acquisition Activity | Targeting the serine/threonine-protein phosphatase-5 in kidney cancer | 30-Sep-2020 | 29-Sep-2022 | 229,525.00 | 435,676.00 |
| Grewal, Harminder | 110 Family Medicine | Health Resources and Services Admin | Rural residency planning and development program | 01-Sep-2020 | 31-Aug-2021 | 223,183.00 | 732,348.00 |
| Chen, Xin Jie | 110 Biochemistry | National Institute on Aging | Novel mechanism of neural and muscular degeneration | 01-Sep-2020 | 31-May-2021 | 412,099.00 | 2,086,399.00 |
| Kim, Bokkyu | 110 Physical Therapy | New York Physical Therapy Association | Transcranial photobiomodulation: illuminating the brain to promote fine hand motor skill learning in chronic stroke survivors - a pilot study | 01-Jul-2020 | 30-Jun-2021 | 9,380.00 | 9,380.00 |
| Klingman, Karen J | 110 Nursing | National Institute for Nursing Research | The SLEEPR study: SLEEp effects on post stroke rehabilitation | 16-Sep-2020 | 30-Jun-2021 | 650,525.00 | 3,051,980.00 |
| Imdad, Aamer | 110 Pediatrics | World Health Organization | Milk other than breast milk | 14-Sep-2020 | 31-Dec-2020 | 10,889.77 | 10,889.77 |
| Paolino, Mr. Kristopher | 110 Medicine | Adaptive Biotechnologies Corporation | ImmuneSense Lyme Study | 10-Aug-2020 | 09-Aug-2021 | 11,803.00 | 11,803.00 |
| Nieman, Gary F | 110 Surgery - General | US Army Medical Research Acquisition Activity | Computationally optimized ventilation in the prehospital hospital setting | 30-Sep-2020 | 29-Sep-2021 | 240,490.00 | 978,607.00 |
| Loh, Dr. Stewart N | 110 Biochemistry | University of Rochester | Development of zinc metallochaperones as mutant p53 targeted anti-cancer drugs | 01-Mar-2020 | 28-Feb-2021 | 33,324.00 | 33,324.00 |
| Duncan, Thomas M | 110 Biochemistry | Campus SF Accounts Multiple Sponsors | Upstate Cancer Center's Molecular Interactions and Drug Screening Core | 01-Oct-2020 | 30-Sep-2021 | 2.00 | 2.00 |
| Duncan, Thomas M | 110 Biochemistry | Multi Funding | Third Party Revenue for Upstate Cancer Center's Molecular Interactions and Drug Screening Core | 01-Oct-2020 | 30-Sep-2021 | 1.00 | 1.00 |
| Desimone, Marisa E. | 110 Medicine | Unitio Incorporated | Type 2 Diabetes (T2D) QI Collaborative | 01-Oct-2020 | 31-Dec-2021 | 1.00 | 1.00 |
| Loh, Dr. Stewart N | 110 Biochemistry | Multiple Sponsors | Research Material Development | 01-Nov-2020 | 31-Oct-2025 | 2,813.36 | 2,813.36 |
| Damron, Timothy A | 110 Surgery - Orthopedics | BoneSupport AB | An Evaluating Study of the Device in the Surgical Treatment of Patients Attending the Hospital Through Reviewing the Device Performance Data (CERAMENT/BONE VOID FILLER Device Registry) | 02-Oct-2020 | 01-Oct-2021 | 4,250.00 | 4,250.00 |
| Mihaila, Dr. Dragos | 110 Neurology | Cerevel Therapeutics | A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parkinson's Disease in Levodopa... (TEMPO 3) | 11-Jun-2020 | 10-Jun-2021 | 10,000.00 | 10,000.00 |
| Monteleone, Mr. Phillip | 110 Pediatrics | Children's Hospital of Philadelphia | ADVL18P1 - An Open-Label Feasibility Study to Assess the Safety and Pharmacokinetics of Enasidenib in Pediatric Patients with Relapsed/Refractory Acute Myeloid Leukemia R/R-AML with an Isocitrate Dehydrogenase-2 IDH2 Mutation | 09-Oct-2020 | 08-Oct-2021 | 3,000.00 | 3,000.00 |
| Wasik, Heather L. | 110 Pediatrics | North American Pediatric Renal Case | Cystinosis Registry Case Report Forms | 06-Oct-2020 | 06-Oct-2021 | 1.00 | 1.00 |
| Perl, Dr. Andras | 110 Medicine | Amgen Incorporated | A Phase 2 Dose Ranging Study to Evaluate the Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE) With Inadequate Response to Standard of Care (SOC) Therapy | 13-Jul-2020 | 12-Jul-2021 | 19,270.50 | 19,270.50 |
| Sivapiragasam, Abirami | 110 Medicine | Merck Sharp and Dohme Corporation | A Phase 3, randomized, placebo-controlled, double-blind clinical study of pembrolizumab (MK3475) with or without lenvatinib (E7080/MK-7902) to evaluate the safety and efficacy of pembrolizumab and lenvatinib as 1L . . . (LEAP-010) | 14-Oct-2020 | 13-Oct-2021 | 28,500.00 | 28,500.00 |
| Mejico, Dr. Luis | 110 Neurology | Amgen Incorporated | An Open-Label, Multiple-Dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine | 29-Jul-2020 | 28-Jul-2021 | 16,285.00 | 16,285.00 |
| Botash, Dr. Ann S | 110 Pediatrics | NYS Department of Health | Child abuse medical provider (CHAMP) training program | 01-Jul-2020 | 30-Jun-2021 | 75,000.00 | 75,000.00 |
| Zoeckler, Jeanette M. | 110 Family Medicine | Western NY Council on Occupational Safety & Health | Capacity building grant | 30-Sep-2020 | 30-Sep-2021 | 22,000.00 | 22,000.00 |
| Blatt, Dr. Steven D | 110 Pediatrics | NYS Office of Mental Health | Healthy Steps | 01-Sep-2016 | 31-Dec-2020 | 387,873.00 | 387,873.00 |
| McGraw, Corey A. | 110 Neurology | Genentech Incorporated | An Open-Label, Multicenter Study to Assess Disease Activity and Biomarkers of Neuronal Damage in Minority Patients with Relapsing Multiple Sclerosis Receiving Treatment with Ocrelizumab | 01-Sep-2020 | 31-Aug-2021 | 16,750.00 | 16,750.00 |
| Brenner, Jay M | 110 Emergency Medicine | Research Foundation for Mental Hygiene | Centers of excellence in culturally competent mental health | 01-Aug-2020 | 31-Oct-2020 | 40,000.00 | 40,000.00 |
| Geier, Christian | 110 Medicine | Ines Mandl Research Foundation | Potential pathogenic functins of HLA-DR positive myeloid subsets in rheumatoid arthritis | 01-Nov-2020 | 31-Oct-2021 | 50,000.00 | 50,000.00 |
| Seth, Rahul | 110 Medicine | FibroGen Inc | A Phase 3, Randomized, Double-Blind Study of Pamrevlumab or Placebo in combination with Gemcitabine Plus Nab-paclitaxel as Neoadjuvant Treatment in Patients with Locally Advanced, Unresectable Pancreatic Cancer | 29-Oct-2020 | 28-Oct-2021 | 35,425.00 | 35,425.00 |
| Fechtner, Robert D. | 110 Ophthalmology | Health Science Center Foundation at Syracuse | Nikon Microscope Purchase | 01-Nov-2020 | 31-Dec-2021 | 182,397.29 | 182,397.29 |
| Weinstock, Dr. Ruth S | 110 Medicine | Lilly USA LLC | A Study of LY900014 in Participants with Type 2 Diabetes using Continuous Glucose Monitoring | 29-Oct-2020 | 28-Oct-2021 | 11,575.00 | 11,575.00 |
| Graziano, Dr. Stephen L | 110 Medicine | Alliance Foundation Trials LLC | CHIO3 Trial: Chemotherapy Combined with Immune Checkpoint Inhibitor for Operable stage IIIA Non-Small Cell Lung Cancer | 17-Nov-2020 | 16-Nov-2021 | 4,250.00 | 4,250.00 |

| | | | | | | | |
|---------------------------|----------------------------------|--|--|-------------|-------------|------------|--------------|
| Simone, Brittany A. | 110 Radiology Oncology | Carol M. Baldwin Breast Cancer Research Fund Inc | Metabolic reprogramming of host immunity in breast cancer | 01-Dec-2020 | 30-Nov-2022 | 25,000.00 | 25,000.00 |
| Lai, Lisa M. | 110 Surgery - General | Carol M. Baldwin Breast Cancer Research Fund Inc | A novel miRNA-based breast cancer screening approach | 01-Dec-2020 | 30-Nov-2022 | 25,000.00 | 25,000.00 |
| Paolino, Mr. Kristopher | 110 Medicine | ContraFect Corporation | A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard of Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections . . . | 19-Nov-2020 | 18-Nov-2021 | 20,475.00 | 20,475.00 |
| Calvert, Dr. Peter D | 110 Ophthalmology | Duke University | Mechanisms of photoreceptor disc maturation | 01-May-2020 | 31-Mar-2021 | 18,627.00 | 18,627.00 |
| Thomas, Stephen J. | 110 Medicine | University of Maryland Baltimore | Clinical core for collaborative influenza vaccine innovation centers (CIVIC): design and execution Option 13A.1 | 30-Jun-2020 | 29-Jun-2021 | 292,423.00 | 292,423.00 |
| Perl, Dr. Andras | 110 Medicine | Lilly USA LLC | A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE) | 11-Nov-2020 | 10-Nov-2021 | 18,750.00 | 18,750.00 |
| Amack, Jeffrey | 110 Cell & Developmental Biology | Syracuse University | Four dimensional prediction and quantification of how physical forces impact organogenesis in zebrafish | 25-Sep-2020 | 31-Aug-2021 | 222,849.00 | 222,849.00 |
| Comito, Melanie A. | 110 Pediatrics | St Baldricks Foundation | St. Baldrick's Infrastructure Grant 2020 | 01-Dec-2020 | 30-Nov-2021 | 50,000.00 | 50,000.00 |
| Ramanathan, Seethalakshmi | 110 Psychiatry | University of Rochester | Effectiveness of a targeted brief intervention for recent suicide attempt survivors | 15-Jul-2020 | 28-Feb-2021 | 53,243.00 | 53,243.00 |
| Calvert, Dr. Peter D | 110 Ophthalmology | National Eye Institute | Mechanisms of photoreceptor protein transport and compartmentalization | 01-Dec-2020 | 30-Nov-2021 | 605,810.00 | 2,630,086.00 |
| Weiner, Dr. Leonard B | 110 Pediatrics | Roche Molecular Systems | Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections (Liverpool Site) | 08-Nov-2020 | 07-Nov-2022 | 1.00 | 1.00 |
| Weiner, Dr. Leonard B | 110 Pediatrics | Roche Molecular Systems | Collection of Respiratory Swab Samples from Patients with Suspected Respiratory Tract Infections (East Syracuse Site) | 08-Nov-2020 | 07-Nov-2022 | 1.00 | 1.00 |
| Satish, Dr. Usha | 110 Psychiatry | View Incorporated | An investigation of the impact of light intensity and light spectrum on sleep quality and overall health and wellbeing of office workers | 01-Nov-2020 | 31-Oct-2021 | 20,000.00 | 20,000.00 |
| Bourboulia, Dimitra | 110 Surgery - Urology | National Institute of General Medical Sciences | Regulation of the extracellular HSP90 chaperone machinery | 01-Dec-2020 | 30-Nov-2021 | 324,000.00 | 1,296,000.00 |
| Mollapour, Mehdi | 110 Surgery - Urology | National Institute of General Medical Sciences | Regulatory mechanisms of the Hsp90 chaperone machinery | 01-Jan-2021 | 31-Dec-2021 | 326,561.00 | 1,944,657.00 |
| Huard, Sharon | 110 Dean - Student Affairs | Multiple Sponsors | Multiple Sponsors Account for Sharon Huard | 01-Dec-2020 | 30-Nov-2025 | 1.00 | 1.00 |
| Thomas, Stephen J. | 110 Microbiology | University of Maryland Baltimore | Clinical core for collaborative influenza vaccine innovation centers (CIVICs): Design & execution Option 13A.1 | 30-Jun-2020 | 29-Jun-2021 | 1.00 | 1.00 |